Palo Alto, Calif.-based Incyte Genomics has ended its search for a CEO. The company made good on its plans to pursue a drug discovery-focused business model in its choice of Paul Friedman, who was president of DuPont Pharmaceuticals Research Laboratories from 1994 until the division was acquired by Bristol-Myers Squibb in September.
Incyte also named Robert Stein, formerly executive vice president of research and preclinical development at DuPont Pharmaceuticals, as president and CSO.
Incyte’s current CEO and co-founder, Roy Whitfield, has been elected chairman of the company’s board of directors, succeeding co-founder Randy Scott. Friedman, Stein, and Julian Baker, managing partner of Baker/Tisch Investments, have also been elected to the board.
During Friedman’s tenure at DuPont Pharmaceuticals (formerly DuPont Merck Pharmaceuticals) Research Laboratories, the number of drug candidate compounds nominated for clinical development tripled, reaching 10 in 2000.
Andrew DePristo has been promoted to president of Basel, Switzerland-based GeneData’s North American subsidiary, GeneData., located in Waltham, Mass. He was formerly vice president and general manager of the company’s East Coast operations.
Silico Insights of Woburn, Mass., has appointed three new members to its scientific board: Sudhir Sahasrabudhe, executive vice president of research at Myriad Genetics; Cathy Wu, professor of biochemistry and molecular biology at Georgetown University Medical Center and vice president of the National Biomedical Research Foundation; and David Schoenfeld, professor in the Department of Medicine at Harvard Medical School and in the Department of Biostatistics at Harvard School of Public Health.